OncoMatch/Clinical Trials/NCT04146298
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Is NCT04146298 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Mutant KRAS G12V-specific TCR transduced autologous T cells and Cyclophosphamide for pancreatic cancer.
Treatment: Cyclophosphamide · Fludarabine · Mutant KRAS G12V-specific TCR transduced autologous T cells · Anti-PD-1 monoclonal antibody — This clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V mutation and HLA-A\*11:01 allele. The theoretical basis of this study is that mutant KRAS antigen-specific TCR transduced autologous Tcells will target and kill HLA-matched mutant KRAS cancer cells but not normal cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS G12V
Patient's tumor must express the KRAS G12V mutation
Required: HRAS G12V
or a G12V mutation in HRAS ... as determined by DNA or RNA sequencing methods
Required: NRAS G12V
or a G12V mutation in ... NRAS, as determined by DNA or RNA sequencing methods
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard chemotherapy
who have received standard chemotherapy
Must have received: surgery and adjuvant chemotherapy
who have received surgery and adjuvant chemotherapy previously
Lab requirements
Blood counts
absolute neutrophil count >= 1000/mm^3; white blood cell count >= 3000/mm^3; platelet count >= 100,000/mm^3; hemoglobin > 8.0 g/dl
Kidney function
serum creatinine <= 1.6 mg/dl
Liver function
serum alt/ast <= 3.0 x uln; total bilirubin <= 1.5 mg/dl (<= 3.0 mg/dl if gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04146298 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard chemotherapy and surgery and adjuvant chemotherapy.
Does this trial require KRAS?
Yes, KRAS G12V is a required biomarker for enrollment.
Does this trial require HRAS?
Yes, HRAS G12V is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS G12V is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages